Clinical scenarios where ACE inhibitors and ARBS are likely to cause AKI

Sharing is caring!

What are the clinical scenarios where ACE inhibitors and ARBS are likely to cause AKI?

Any clinical circumstance where perfusion to the kidney is impaired will cause a decline in glomerular filtration rate (GFR) and AKI by inducing efferent arteriolar vasodilatation through blockade of angiotensin II production or receptor binding. Clinical scenarios include:

  • • Disease states associated with hypotension
  • • Decreased blood volume (i.e., diuretics, diarrhea, vomiting, etc.)
  • • Decreased effective circulating blood volume (i.e., CHF, cirrhosis, nephrotic syndrome, etc.)
  • • Critical renal artery stenosis
  • • Treatment with medications such as NSAIDs, calcineurin inhibitors (CNIs), and vasoconstrictors

The typical scenario is that the GFR continues to decline with ACE inhibitor/ARB therapy and does not stabilize until drug withdrawal or correction of the underlying disease process.

Stabilization of kidney function, without hyperkalemia or hypotension, with continued ACEi/ARB therapy is likely associated with beneficial effects on both the heart and the kidneys.

Sharing is caring!

You cannot copy content of this page


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top